Analysts Set XOMA Royalty Corporation (NASDAQ:XOMA) PT at $53.75

XOMA Royalty Corporation (NASDAQ:XOMA) has been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $53.75.

XOMA has been the topic of several recent analyst reports. Benchmark cut XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. HC Wainwright lowered XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a research report on Thursday, April 30th. Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Lucid Cap Mkts downgraded shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Finally, Weiss Ratings upgraded shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 29th.

XOMA Royalty Price Performance

Shares of NASDAQ XOMA opened at $43.00 on Monday. The firm has a market cap of $539.22 million, a P/E ratio of 27.39 and a beta of 0.86. XOMA Royalty has a twelve month low of $22.29 and a twelve month high of $43.00. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.96. The company has a 50 day moving average of $41.69 and a 200 day moving average of $33.06.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The business had revenue of $12.32 million during the quarter, compared to the consensus estimate of $13.91 million. As a group, research analysts expect that XOMA Royalty will post 0.9 EPS for the current fiscal year.

Institutional Investors Weigh In On XOMA Royalty

A number of large investors have recently added to or reduced their stakes in XOMA. JPMorgan Chase & Co. lifted its holdings in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares during the period. Russell Investments Group Ltd. increased its position in XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in XOMA Royalty during the fourth quarter valued at $27,000. Dimensional Fund Advisors LP increased its position in XOMA Royalty by 4.5% during the third quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock valued at $1,124,000 after acquiring an additional 1,269 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,523 shares during the period. Institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.